Clinical Evaluation of a New Reserpine Derivative,SU-3118 (Syrosingopine)

Abstract

Get full access to this article

View all access options for this article.

References

Spittel, J.A. , JR. : Symposium on medical treatment of hypertension: Selection of the therapeutic agent for the patient. Proc. Staff Meet. Mayo Clin., 33: 313, 1958.

Kert, M.J. , Penzell, Y. , Nordyke, R.A. , Roth, S.I. , Smith, L.A. , AND Westergart, J. : Long-term administration of reserpine in hypertension. Angiology ., 8: 466, 1957.

Achor, R.W.P. , Hanson, N.O. , AND Gifford, R.W., JR. : Hypertension treated with rauwolfia serpentina (whole root) and with reserpine. J. A. M. A., 159: 841, 1958.

PERSONAL COMMUNICATION: Ciba Pharmaceutical Products, Inc., Summit, New Jersey.

Darvill, F.T. , JR : SU-3118 (carbethoxysyringoyl methyl reserpate): A placebo study of antihypertensive potency and of side effects. Antibiotic M., 5: 598, 1958.

Wilkins, R.W. : New drugs for hypertension with special reference to Chlorothiazide. New England J. Med., 257: 1026, 1957.